Sign in

SNGX on Nasdaq

SOLIGENIX, INC.

In its 2026 annual report the company says: “We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (a proposed proprietary name of SGX301 or synthetic hypericin sodium), a novel photodynamic therapy, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma.”5 It is headquartered in Princeton, United States.2 Its shares trade on Nasdaq under the symbol SNGX.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with BullFrog AI Holdings, Inc., Nkarta Therapeutics (United States) or Serina Therapeutics, Inc., or pick any stock.

  • TickerSNGX on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersPrinceton, United States2
  • Incorporated inDE3
  • Business address29 Emmons Drive, Suite B-10, Princeton, Nj 085403
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300MN2EF9LQHLT8172
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Corporate Creations Network Inc., 19810 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 21150332

See how the biggest companies compare on our leaderboards

We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We maintain two active business segments: Specialized BioTherapeutics and Public Health Solutions.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-7907.7%Operating margin6
-6925.1%Net margin6
-85.8%Revenue growth, 20246
-200.7%Return on equity6
0.00×Debt to equity7

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue2¢$119.4K
  • Research and development91¢$5.2M
  • Income tax7¢$409.1K

Out of $119.4K in revenue.6 The company lost money this year.

Financial statements

Revenue89101176$119.4K in 2024−97% since 2019
0$2.0M$4.0M$6.0M2019: $4.6M$4.6M20192020: $2.4M$2.4M2020−49%2021: $824.3K$824.3K2021−65%2022: $948.9K$948.9K2022+15%2023: $839.4K$839.4K2023−12%2024: $119.4K$119.4K2024−86%
Gross profit8910117$97.3K in 2023−91% since 2019
0$500.0K$1.0M$1.5M2019: $1.1M$1.1M20192020: $538.5K$538.5K2020−49%2021: $95.6K$95.6K2021−82%2022: $398.1K$398.1K2022+316%2023: $97.3K$97.3K2023−76%
Operating income89101176-$9.4M in 2024−10% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M02019: -$10.5M-$10.5M20192020: -$18.6M-$18.6M2020+76%2021: -$13.1M-$13.1M2021−30%2022: -$14.2M-$14.2M2022+9%2023: -$7.7M-$7.7M2023−46%2024: -$9.4M-$9.4M2024+23%
Net income89101176-$8.3M in 2024−12% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M02019: -$9.4M-$9.4M20192020: -$17.7M-$17.7M2020+89%2021: -$12.6M-$12.6M2021−29%2022: -$13.8M-$13.8M2022+10%2023: -$6.1M-$6.1M2023−55%2024: -$8.3M-$8.3M2024+35%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Total revenues$119.4K
Cost of revenues-$119.4K
Research and development$7.5M$5.2M
General and administrative$4.4M$4.2M
Total operating expenses$11.8M$9.4M
Loss from operations-$11.8M-$9.4M
Foreign currency transaction (loss) gain-$11.8K$1.6K
Interest income, net$270.2K$214.0K
Research and development incentives-$25.5K
CARES Act employee retention credit$312.8K
Other income$125$43
Change in fair value of convertible debt$260.9K
Total other income$258.5K$763.8K
Net loss before income taxes-$11.6M-$8.7M
Income tax benefit$506.6K$409.1K
Net loss applicable to common stockholders-$11.1M-$8.3M
Basic net loss per share (in Dollars per share)-$2.14-$4.98
Diluted net loss per share (in Dollars per share)-$2.14-$4.98
Basic weighted average common shares outstanding (in Shares)5.2M shares1.7M shares
Diluted weighted average common shares outstanding (in Shares)5.2M shares1.7M shares

Compare SOLIGENIX, INC. with another company

Corporate structure

SOLIGENIX, INC. sits at the top of its group. 7 entities, 4 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of SOLIGENIX, INC.

  • SOLIGENIX, INC. Princeton, New Jersey, United States
    • Enteron Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Orasomal Technologies Inc. Subsidiary · Delaware, United States
    • Soligenix BioPharma Canada Incorporated Subsidiary · Canada
    • Soligenix Biopharma HI, Inc. Subsidiary · Hawaii, United States
    • Soligenix NE B.V. Subsidiary · Netherlands
    • Soligenix UK Limited Subsidiary · United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What SOLIGENIX, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$8.8K6 Dec 31, 2025$6.1K6 Dec 31, 2024+43.5%
Operating-lease assets (leased space)$355.0K6 Dec 31, 2025$109.0K6 Dec 31, 2024+225.8%

Properties, in its own words

We currently lease approximately 6,200 square feet of office space at 29 Emmons Drive, Suite B-10 in Princeton, New Jersey. Pursuant to an amendment in May 2025, the lease has been extended through October 2028. This office space currently serves as our corporate headquarters, and both of our business segments (Specialized BioTherapeutics and Public Health Solutions), operate from this space. The current monthly rent is $11,625 through October 2026 and increases to $11,883 in November 2026 and to $12,142 in November 2027 where it remains until expiration. Our office space is sufficient for our current needs. We may add new space or expand existing space as we add employees, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.

Item 2 of the 10-K filed Mar 31, 2026.5

Leadership

Who has led SOLIGENIX, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael T. Sember2006
  2. Christopher Schaber2006–now

Chair

  1. Christopher Schaber2010–now

President

  1. Christopher Schaber2006–now

Chief financial officer

  1. Evan Myrianthopoulos2006–2011
  2. Joseph Michael Warusz2013–2016
  3. Karen R. Krumeich2016–2018
  4. Jonathan L. Guarino2019–now
2010201520202025
Board members and other officers (24)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Enteron Pharmaceuticals, Inc. Delaware4
  • Orasomal Technologies Inc. Delaware4
  • Soligenix BioPharma Canada Incorporated Canada4
  • Soligenix Biopharma HI, Inc. Hawaii4
  • Soligenix NE B.V. Netherlands4
  • Soligenix UK Limited United Kingdom4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • DOR BIOPHARMA INCApr 1, 2002 to Sep 29, 20093
  • ENDOREX CORPSep 16, 1996 to Oct 24, 20013
  • IMMUNOTHERAPEUTICS INCAug 8, 1995 to Apr 30, 19963

Timeline

  1. Sep 21, 20268-K Bylaws or fiscal year changed; Shareholder vote; Other events42
  2. Jun 26, 20268-K Other events43
  3. Jun 12, 20268-K Listing notice or transfer; Executive or director change; Other events44
  4. May 28, 20268-K Other events45
  5. Apr 28, 20268-K Other events46
  6. Feb 12, 20268-K Other events47
  7. Jan 23, 20268-K Other events48
  8. Nov 18, 20258-K Listing notice or transfer49
  9. Sep 29, 20258-K Entered a material agreement; Other events50
  10. Aug 18, 20258-K Other events51
  11. Aug 15, 20258-K Listing notice or transfer52
  12. Jul 31, 20258-K Other events53
  13. Sep 1, 2006New chief executive Christopher Schaber becomes CEO15
  14. Apr 10, 2006New chief executive Michael T. Sember becomes CEO14

Calendar

Coming up

  1. Nov 6, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.58) a share, on Nov 7, 2025.54

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

257 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 55 major events, 59 insider forms, 4 large holders, 119 other. The latest 20:

  1. Oct 13, 20264 EDGAR
  2. Oct 13, 20264 EDGAR
  3. Oct 13, 20264 EDGAR
  4. Oct 13, 20264 EDGAR
  5. Oct 13, 20264 EDGAR
  6. Oct 13, 20264 EDGAR
  7. Oct 13, 20264 EDGAR
  8. Sep 21, 20268-K EDGAR
  9. Sep 18, 20264 EDGAR
  10. Sep 18, 20264 EDGAR
  11. Sep 18, 20264 EDGAR
  12. Sep 18, 20264 EDGAR
  13. Aug 7, 2026424B3 EDGAR
  14. Aug 7, 2026424B3 EDGAR
  15. Aug 7, 2026424B3 EDGAR
  16. Aug 7, 2026424B3 EDGAR
  17. Aug 7, 202610-Q EDGAR
  18. Aug 3, 2026ARS EDGAR
  19. Aug 3, 2026DEFA14A EDGAR
  20. Aug 3, 2026DEF 14A EDGAR

The 257 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 7 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 2, 2025SCHABER CHRISTOPHER JCHAIRMAN, CEO AND PRESIDENTBuy15,132$1.32$20.0KForm 4
May 18, 2022Straube RichardCMO (Consulting)Buy8,000$0.50$4.0KForm 4
May 18, 2022SCHABER CHRISTOPHER JCHAIRMAN, CEO AND PRESIDENTBuy20,000$0.44$8.8KForm 4
Dec 17, 2021SCHABER CHRISTOPHER JCHAIRMAN, CEO AND PRESIDENTBuy7,000$0.74$5.2KForm 4
Dec 15, 2021Guarino Jonathan L.CFOBuy1,000$0.70$700Form 4
Dec 14, 2021Guarino Jonathan L.CFOBuy10,000$0.71$7.1KForm 4
Dec 14, 2021SCHABER CHRISTOPHER JCHAIRMAN, CEO AND PRESIDENTBuy10,000$0.73$7.3KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Christopher J. Schaber CEO & President59$559.2K$1.1M58
2025Oreola Donini CSO & Senior VP54$322.9K$562.0K58
2025Jonathan Guarino CFO & Senior VP$263.7K$516.2K58
2025Richard C. Straube CMO & Senior$169.0K$183.5K58
2024Christopher J. Schaber CEO & President59$540.3K$832.6K58
2024Oreola Donini CSO & Senior VP54$312.0K$432.1K58
2024Jonathan Guarino CFO & Senior VP$254.8K$399.2K58
2024Richard C. Straube CMO & Senior$197.0K$268.7K58

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Citadel Advisors LLC209,507$83.0K0.0%New
Jane Street Group, LLC207,492$82.2K0.0%New
XTX Topco Ltd157,119$62.2K0.0%+136,320
Geode Capital Management, LLC120,267$47.6K0.0%No change
Vanguard Capital Management LLC81,005$32.1K0.0%+22,605
Vanguard Fiduciary Trust Co53,914$21.4K0.0%No change
Northern Trust Corp38,046$15.1K0.0%New
Morgan Stanley3,592$1.4K0.0%No change
Jones Financial Companies Lllp1,236$5070.0%+1,136
Jpmorgan Chase & Co245$980.0%−60
Plante Moran Financial Advisors, LLC209$830.0%No change
Virtu Financial LLC60,903$240.0%New
Albion Financial Group /ut1$10.0%No change
SBI Securities Co., Ltd.2$10.0%−400
Royal Bank Of Canada5$00.0%New
Osaic Holdings, Inc.1$00.0%−1
Caitong International Asset Management Co., Ltd1$00.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How SOLIGENIX, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSOLIGENIX, INC.1
  • CIK0000812796
  • Employer ID (EIN)41-15050295
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address29 Emmons Drive, Suite B-10, Princeton, NJ 085401
  • Phone609-538-82001
  • Shares outstanding21,765,479 as of Jul 31, 202613
  • Public float$4.6M as of Jun 30, 20255
  • AuditorCherry Bekaert LLP, Tampa, Florida PCAOB ID 677; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceAug 8, 19951
  • Filings1,423 in all: 4 (293), 8-K (255), 424B3 (122), 10-Q (58), CORRESP (55), EFFECT (51), SC 13D/A (51), 3 (41)1
    All 61 form types

    DEFA14A (39), 10QSB (37), SC 13G/A (36), UPLOAD (33), SC 13G (31), DEF 14A (30), POS AM (29), S-1/A (25), PRE 14A (20), 10-K (18), S-1 (18), 10KSB (13), 10KSB/A (12), 424B5 (11), S-3 (11), SC 13D (11), 4/A (9), CT ORDER (9), S-3/A (9), S-8 (9), REGDEX (8), 424B4 (7), D (7), 425 (6), 8-K/A (6), S-2/A (5), 10QSB/A (4), ARS (4), SB-2/A (4), DEFR14A (3), PRER14A (3), SCHEDULE 13G (3), 10-K/A (2), 25-NSE (2), 8-A12B (2), 8-A12G (2), NT 10-Q (2), SB-2 (2), 3/A (1), 8-A12B/A (1), AW (1), CERTNAS (1), DEFC14A (1), DRS (1), NT 10-K (1), PRE 14C (1), PREC14A (1), PREN14A (1), S-1MEF (1), S-2 (1), S-4 (1), S-4/A (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 7, 2026
    Proxy statement (DEF 14A) Aug 3, 2026
    Latest 8-K (8-K) Sep 21, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.01 per shareSNGXNasdaq

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks SOLIGENIX, INC. names in Item 1A of its 10-K filed Mar 31, 2026: 46 risks under these headings, as written.5

  • Risks Related to our Business
  • Risks Related to our Intellectual Property
  • Risks Related to Technology and Intellectual Property
  • Risks Related to our Securities
  • We have had significant losses and anticipate future losses; if additional funding cannot be obtained, we may reduce or discontinue our product development and commercialization efforts.
  • Our losses from operations, negative cash flows, and shareholders' deficit as of December 31, 2025 raise substantial doubt about our ability to continue as a going concern absent obtaining adequate new debt or equity financings.
  • The report of our independent registered accounting firm on our audited financial statements for the fiscal year ended December 31, 2025 contains an explanatory paragraph relating to our ability to continue as a going concern.
  • If we are unable to develop our product candidates, our ability to generate revenues and viability as a company will be significantly impaired.
  • We expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance.
  • We have no approved products on the market and therefore do not expect to generate any revenues from product sales in the foreseeable future, if at all.
  • There may be unforeseen challenges in developing our biodefense products.
  • We are dependent on government funding, which is inherently uncertain, for the success of our biodefense operations.
The other 38 risks
  • If the parties we depend on for supplying our drug substance raw materials and certain manufacturing-related services do not timely supply these products and services, it may delay or impair our ability to develop, manufacture and market our products. We do not have or anticipate having internal manufacturing capabilities.
  • We rely on third parties for pre-clinical and clinical trials of our product candidates and, in some cases, to maintain regulatory files for our product candidates. If we are not able to maintain or secure agreements with such third parties on acceptable terms, if these third parties do not perform their services as required, or if these third parties fail to timely transfer any regulatory information held by them to us, we may not be able to obtain regulatory approval for, or commercialize, our product candidates.
  • The manufacturing of our products is a highly exacting process, and if we or one of our materials suppliers encounter problems manufacturing our products, our business could suffer.
  • We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.
  • Even if approved, our products will be subject to extensive post-approval regulation.
  • Even if we obtain regulatory approval to market our product candidates, our product candidates may not be accepted by the market.
  • We do not have extensive sales and marketing experience and our lack of experience may restrict our success in commercializing some of our product candidates.
  • Our products, if approved, may not be commercially viable due to change in health care practice and third-party reimbursement limitations.
  • Our product candidates may cause serious adverse events or undesirable side effects which may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.
  • If we fail to obtain or maintain orphan drug exclusivity for our product candidates, our competitors may sell products to treat the same conditions and our revenue will be reduced.
  • Our business strategy includes the potential receipt and monetization of PRVs, but there can be no assurance that we will qualify for, receive or realize value from any such voucher, and changes in the PRV programs or our development plans could materially and adversely affect this aspect of our business.
  • Federal and/or state health care reform initiatives could negatively affect our business.
  • We may not be able to retain rights licensed to us by third parties to commercialize key products or to develop the third-party relationships we need to develop, manufacture and market our products.
  • We may suffer product and other liability claims; we maintain only limited product liability insurance, which may not be sufficient.
  • We may use hazardous chemicals in our business. Potential claims relating to improper handling, storage or disposal of these chemicals could affect us and be time consuming and costly.
  • We may not be able to compete with our larger and better financed competitors in the biotechnology industry.
  • Competition and technological change may make our product candidates and technologies less attractive or obsolete.
  • Our business could be harmed if we fail to retain our current personnel or if they are unable to effectively run our business.
  • Instability and volatility in the financial markets could have a negative impact on our business, financial condition, results of operations, and cash flows.
  • Changes in U.S. and international trade policies may adversely impact our business and operating results.
  • Adverse developments affecting financial institutions such as actual events or concerns involving liquidity, defaults or non-performance, could adversely affect our operations and liquidity.
  • We may not be able to utilize all of our net operating loss carryforwards.
  • Global pathogens that could have an impact on financial markets, materials sourcing, patients, governments and population (e.g. COVID-19).
  • Escalation of armed conflict and geopolitical instability in the Middle East, including tensions involving Israel, Iran and the United States, could materially disrupt our clinical development activities in general and specifically those relating to SGX945 (dusquetide) for the treatment of BD.
  • We may be unable to commercialize our products if we are unable to protect our proprietary rights, and we may be liable for significant costs and damages if we face a claim of intellectual property infringement by a third party.
  • We may be involved in lawsuits to protect or enforce our patents, which could be expensive and time consuming.
  • If we infringe the rights of third parties we could be prevented from selling products, forced to pay damages, and defend against litigation.
  • Our strategy includes an increasing dependence on technology in our operations. If any of our key technology fails, our business could be adversely affected.
  • Our use of generative artificial intelligence tools in our operations may expose us to risks related to confidentiality, accuracy, regulatory compliance and intellectual property ownership or rights.
  • A cybersecurity incident could negatively impact our business and our relationships with our employees, service providers, patients, clinical study sites and government agencies.
  • The price of our common stock may be highly volatile.
  • If we fail to meet Nasdaq’s listing requirements, we could be removed from The Nasdaq Capital Market, which would limit the ability of broker-dealers to sell our securities and the ability of shareholders to sell their securities in the secondary market and negatively impact our ability to raise capital.
  • Shareholders may suffer substantial dilution related to issued common stock warrants, and options.
  • Our shares of common stock are thinly traded, so stockholders may be unable to sell at or near ask prices or at all if they need to sell shares to raise money or otherwise desire to liquidate their shares.
  • We do not currently intend to pay dividends on our common stock in the foreseeable future, and consequently, our stockholders’ ability to achieve a return on their investment will depend on appreciation in the price of our common stock.
  • Upon our dissolution, our stockholders may not recoup all or any portion of their investment.
  • The issuance of our common stock pursuant to the terms of the asset purchase agreement with Hy Biopharma Inc. may cause dilution and the issuance of such shares of common stock, or the perception that such issuances may occur, could cause the price of our common stock to fall.
  • Our Board of Directors can, without stockholder approval, cause preferred stock to be issued on terms that adversely affect holders of our common stock.

Legal proceedings

From time to time, we are a party to claims and legal proceedings arising in the ordinary course of business. Our management evaluates our exposure to these claims and proceedings individually and in the aggregate and allocates additional monies for potential losses on such litigation if it is possible to estimate the amount of loss and if the amount of the loss is probable.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
    SEC EDGAROther events
  44. 44
  45. 45
    SEC EDGAROther events
  46. 46
    SEC EDGAROther events
  47. 47
    SEC EDGAROther events
  48. 48
    SEC EDGAROther events
  49. 49
  50. 50
  51. 51
    SEC EDGAROther events
  52. 52
  53. 53
    SEC EDGAROther events
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58